Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery

Running, not enrolling · Phase 1

Conditions studied: Pancreatic Cancer

In brief

The purpose of this study is to evaluate the safety or treating pancreatic cancer with surgery to remove cancerour tissue, followed by atezolizumab, followed by a personalized cancer vaccine (PCV), and then with chemotherapy.

Key facts

Study ID: NCT04161755
Run by: Memorial Sloan Kettering Cancer Center
People needed: 29
Starts: 2019-12-13
Expected to finish: 2026-11-11
Last updated by the study team: 2026-01-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Subjects must be >/= 18 years of age at time of informed consent
Able to comply with the study protocol, in the investigator's judgment
Subjective with radiographically resectable primary pancreatic tumors with radiographic features consistent with adenocarcinoma will be evaluated for surgical resection
Tumors must be radiographically resectable, defined as:
A clear fat plane around the celiac and superior mesenteric arteries
patent superior mesenteric and portal veins without primary tumor involvement
No encasement of the superior mesenteric vein or portal veins
No encasement of the superior mesenteric or hepatic arteries
No metastatic disease
No extra-regional nodal disease
Subjects with histologically confirmed resected ductal pancreatic adenocarcinoma with macroscopic complete resection (R0 and R1) will be selected for neoantigen vaccine creation. Subjects with neuroendocrine (and mixed type) tumors are excluded
Pancreatic cancer surgical staging: T 1-3, N0-2, M0
° Per AJCC 8th edition staging
Performance status of 0 or 1 on Eastern Cooperative Oncology Group (ECOG) Scale of Performance Status (Section 20.0 APPENDICES, Appendix1)
Subjects must not have had prior chemotherapy, radiation therapy, or immunotherapy for PDAC
Subjects must be able to read, understand, and sign informed consent
Women of childbearing potential must have a negative serum or urine pregnancy test within 14 days prior to study initiation
For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures that result in a failure rate of less than (<) 1% per year during the treatment period and for at least 5 months after the last dose of atezolizumab and for at least 90 days after the last dose of RO7198457. A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (>/= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus)
For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom during the entire study period and up to 90 days after last administration of RO7198457. Male participants should not donate sperm for 90 days after the last dose of RO7198457
Examples of contraceptive methods with a failure rate of <1% per year include bilateral tubal ligation, male sterilization and established proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices and copper intrauterine devices
Hormonal contraceptive methods must be supplemented by a barrier method plus spermicide
The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception

You may not qualify if…

A subject will not be eligible for inclusion in this study if any of the following criteria apply:
Prior neoadjuvant treatment or radiation therapy for PDAC
Prior therapy with uPD-1 antibody or any other immune therapy
Borderline resectable, locally unresectable or metastatic PDAC
Pancreas tumor histology other than PDAC
Pregnancy, breastfeeding, or intending to become pregnant during the study or within 90 days after the last dose of study treatment
Life expectancy less than 12 weeks
Inability to comply with study and/or follow-up procedures
Any other malignancy for which the patient is undergoing active treatment which will be concurrent with the investigational agent in this study.
Patients with unresolved Clavien-Dindo >/= Grade 3 (Section 20.0 APPENDICES ,Appendix 2) postoperative complications
Actie, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy, defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment
Active tuberculosis
Known infection with hepatitis B or C, or history of human immunodeficiency virus (HIV) infection or subjects receiving immunosuppressive or myelosuppressive medications that would, in the opinion of the investigator, increase the risk of serious neutropenic complications
Known hypersensitivity or allergy to the active substance or to any of the excipients of RO7198457, atezolizumab, oxaliplatin, leucovorin, irinotecan, or fluorouracil
Serious medical risk factors involving any of the major organ systems, or serious psychiatric disorders, which could compromise the subject's safety or the study data integrity. These include, but are not limited to:
History of connective tissue disorders (e.g., lupus, scleroderma, arteritis nodosa)
History of interstitial lung disease, slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis, or multiple allergies
History of the following within 6 months prior to RO7198457 administration: a myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, New York Heart Association (NYHA) Class III-IV heart failure, uncontrolled hypertension, clinically significant cardiac dysthythmia, or electrocardiogram (ECG) abnormality (exceptions: atrial fibrillation, paroxysmal supraventricular tachycardia), cerebrovascular accident, transient ischemic attack,, or seizure disorder
History or autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, vasculitis, or glomerulonephritis with the following caveats:
Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible
Patient with controlled type 1 diabetes mellitus on a stable insulin regimen may be eligible
Patients type 2 diabetes mellitus may be eligible
° Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., no psoriatic arthritis) may be eligible provided that they meet the following conditions:
Rash must cover less than 10% of the body surface area (BSA)
Disease is well controlled at baseline and only requires low potency topical steroids

Where it is running

Memorial Sloan Kettering Basking Ridge (All Protocol Activities) — Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth (All Protocol Activities) — Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen (All Protocol Activities) — Montvale, New Jersey, United States
Memorial Sloan Kettering Cancer Center @ Commack (All Protocol Activities) — Commack, New York, United States
Memorial Sloan Kettering Westchester (All Protocol Activities) — Harrison, New York, United States
Memorial Sloan Kettering Cancer Center — New York, New York, United States
Memorial Sloan Kettering Nassau (All Protocol Activities) — Rockville Centre, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.